Extended Data Fig. 8: Bcat2 inhibitor impedes PDAC development.
From: BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma
a-f, Alleviation of PanIN progression by Bcat2 inhibitor in KC mice at late stage. Representative images and quantification of alcian blue (a, n = 5 biologically independent animals per group, b, each 5 fields, mean ± s.e.m., two-tailed t-test)-, sirius red (c, n = 5 per group biologically independent animals, d, each 5 fields, mean ± s.e.m., two-tailed t-test)-, Ki67 (e, n = 5 biologically independent animals per group, f, each 10 fields, mean ± s.e.m., two-tailed t-test)-, and CK19 (g, n = 5 biologically independent animals per group)-staining (scale bars: a, c: 50 μm; e, g: 12.5 μm). h, i, No significant change of food intake (h, mean ± s.e.m. of n = 7 biologically independent samples, two-tailed t-test) and body weight (i, mean ± s.e.m. of n = 5 biologically independent animals) of Control (Con) and KC mice by Bcat2 inhibitor treatment. j, k No effect on glucose homeostasis in Con and KC mice with Bcat2 inhibitor treatment. Glucose tolerance test (GTT) and insulin tolerance test (ITT) were analyzed (mean ± s.e.m. of n = 5 biologically independent animals, n.s. donates for no significance, detailed p value is available in Supplementary Table 3, two-tailed t-test).
